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Background. Even if various pathophysiological events have been proposed as explanations, the putative cause of sudden hearing
loss remains unclear. Objectives. To investigate and to reveal associations (if any) between the main iron-related gene variants and
idiopathic sudden sensorineural hearing loss. Study Design. Case-control study. Materials and Methods. A total of 200 sudden
sensorineural hearing loss patients (median age 63.65 years; range 10–92) were compared with 400 healthy control subjects. The
following genetic variants were investigated: the polymorphism c.−8CG in the promoter of the ferroportin gene (FPN1; SLC40A1),
the two isoforms C1 and C2 (p.P570S) of the transferrin protein (TF), the amino acidic substitutions p.H63D and p.C282Y in the
hereditary hemochromatosis protein (HFE), and the polymorphism c.–582AG in the promoter of the HEPC gene, which encodes
the protein hepcidin (HAMP). Results. The homozygous genotype c.−8GG of the SLC40A1 gene revealed an OR for ISSNHL risk
of 4.27 (CI 95%, 2.65–6.89; 𝑃 = 0.001), being overrepresented among cases. Conclusions. Our study indicates that the homozygous
genotype FPN1 −8GG was significantly associated with increased risk of developing sudden hearing loss. These findings suggest
new research should be conducted in the field of iron homeostasis in the inner ear.
1. Introduction
Sudden sensorineural hearing loss (SSNHL) represents an
acute inner ear disorder, mostly unilateral, that generally
affects adults worldwide, even if higher occurrence rates are
reported in developed countries [1, 2]. It has been estimated
that SSNHL has an overall incidence rate of 5–20/100,000
individuals per year, though this is most likely an under-
estimate [2, 3]. Several pathophysiological mechanisms for
idiopathic sudden sensorineural hearing loss (ISSNHL) have
been proposed in the literature: local hypoxic/ischemic events
(including coagulopathies, hypotension, and thromboem-
bolism), autoimmune andmetabolic disorders, inner ear viral
infections, rupture of the inner ear membranes, free radicals
induced-damage, neuronal damage, and dysregulation of
the local inflammatory response [3–5] leading to transient
or permanent dysfunction of cochlear microcirculation [6].
More than isolated events, they could be considered as part
of a unique vicious circle determining a sudden clinical
manifestationwhen local recovery or residual functions reach
a subjective threshold or trigger point.
To contribute to the comprehension of the homeostatic
events, the present study focused on divalent metallic ions
and in particular on iron metabolism [7]. There is a growing
interest in the association between iron metabolism and
oxidative stress; as it has been reported iron excess is a
potential cause of increased oxidative stress and therefore
involved in cellular injury and death. Iron is an essential
nutrient, but its divalent form (Fe2+), as well as other divalent
metal ions, also has the capacity to enhance redox cycling and
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free radical formation [8, 9]. Iron-mediated oxidative stress
is hypothesized to be involved in the pathogenesis of several
degenerative disorders, including thrombosis, venous ulcers,
chronic venous disease, and central nervous system disorders
such as multiple sclerosis or neoplasms [10–13]. In addition,
a novel iron-driven etiopathogeneticmechanism, responsible
for increase in free radical generation, has been formulated in
degenerative skin lesions appearance comprehending coex-
istence of local iron overload and iron homeostasis gene-
variants [14]. Accordingly, similar conditions could be poten-
tially associated with sudden hearing loss [15]. Therefore,
divalent ions homeostasis could be a central pathway involved
in the pathophysiology of sudden hearing loss [16, 17]. In
fact, the one of the known models of hearing loss in Pendred
syndrome is iron/free radical stress-mediated [18]. The main
genes and their variants we selected and investigated with
possible effects on tissue injury [10, 19] are described below.
TheHFE gene (6p21.3–22.2) encodes amembrane protein
of 348 amino acids that belongs to the MHC class I family.
The protein is normally expressed in cryptal enterocytes of
the duodenum, liver, placenta, kidney, plasma, and platelets.
Complexingwith beta 2microglobulin and transferrin recep-
tor (TFR2), it plays a crucial role in iron homeostasis,
and, when mutated, it is believed to be responsible for
hemochromatosis, variegate porphyria, and microvascular
complications of diabetes. Variants and/or mutated proteins
bind to the transferrin receptor and reduce its affinity for
iron-loaded transferrin. Thus, they finally unbalance the
iron intake. Recent increasing interest in neurodegenerative
disorders mediated by iron overload has highlighted theHFE
gene among candidates for further investigations into iron
homeostasis involvement in similar conditions. A review of
the literature suggests a potential role even in iron-mediated
hearing loss also in the past [20, 21]. Finally, it is important
to note that the HFE gene is also expressed in the brain,
spinal cord, cortex, and cerebellum [22, 23]. Thus, it could
be directly involved or responsible for specific conditions
concerning the central nervous system.
The FPN1 (SLC40A1) gene is located on chromosome 2
(2q32), and it encodes a protein (ferroportin) of 570 amino
acids with the specific function of exporting iron out from
cells in the basolateral space, except for the reticuloen-
dothelial cells, which can spread iron ions into the blood
circulation. Consequently, FPN1 plays a crucial role in iron
homeostasis [24], and, generally, it has the opposite function
of the DMT1 protein product [25], which allows intracellular
passage of divalent iron (Fe2+). Ferroportin is expressed in
different tissues, though to the best of our knowledge there are
no previous reported studies that document its localization
into the cochlea. Similar to other iron genes, it undergoes iron
regulation at the transcriptional and translational level [26–
28].
Another important gene related to ferroportin expression
and function is the HEPC (19q13.1) gene encoding the
protein hepcidin (HAMP). This protein is a 25-amino-acid
peptide, derived from the cleavage of an 84-amino-acid long
propeptide that is mainly synthesized by hepatocytes and is
a major regulator of iron balance activity via binding to the
FPN1 protein on the cell membrane, suppressing it [29, 30].
HEPC expression and its role in iron homeostasis may play a
crucial role in different conditions [31].
The TF gene (3q22.1) encodes for the protein transferrin,
which forms a stable complex with the HFE protein, which
facilitates iron transfer via the transferrin receptor. The
function of this protein is to transport iron from the intestine,
reticuloendothelial system, and liver parenchymal cells to all
proliferating cells in the body. The effect of HFE on iron
absorption depends on its relationship with the transferrin
receptor. HFE variants affect TF binding, determining a loss
of HFE-repressor function for TF uptake, thereby increasing
iron transport within the cells.
As there are no previous reports in the literature about the
role of iron metabolism regulatory genes in the pathophysi-
ology of SSNHL, we proceeded to evaluate if specific single
nucleotide polymorphisms within the main iron genes are
potentially involved in the susceptibility to SSNHL.
2. Materials and Methods
2.1. Study Design Patient and Control Enrolment. The re-
search was designed as a case-control study. A total of 200
patients (104 females and 96 males), affected by idiopathic
sudden sensorineural hearing loss (ISSNHL) and referred
to the ENT and Audiology Department of the University
Hospital of Ferrara from 2009 to 2013, were enrolled for
this study. According to the current literature, ISSNHL was
defined as a sudden hearing loss (≥30 dB HL), within 3
consecutive frequencies, developing over 72 hours [32].
All patients underwent a complete clinical interview with
a complete audiological evaluation, includingmicrootoscopy,
tonal and speech audiometry, impedancemetry, auditory
brainstem responses (ABRs), and MRI with gadolinium to
rule out retrocochlear pathology.
The patients were enrolled in the study after diagnosis of
ISSNHLmade by experienced audiologists. Exclusion criteria
were specific causes of sudden hearing impairment such as
meningitis, traumas, or surgery outcomes and complications.
For each patient, a Pure Tone Average hearing threshold
(PTA dBHL) was estimated from the hearing levels at 0.5, 1,
2, and 4 kHz. The average degree of hearing loss was then
classified into the following groups, according to a modified
method fromClark [33]: normal hearing (10–15 dBHL), mild
hearing loss (16–40 dB HL), moderate hearing loss (41–70 dB
HL), severe hearing loss (71–90 dBHL) and profound hearing
loss (>90 dBHL).The type of hearing loss was then evaluated
according to the Tran Ba Huy classification [34] and thereby
stratified into five types: A, B, C, D, and E.
The control group consisted of 400 healthy volunteers
with no personal or familial history of previous SSNHL and
theywere completelymatchedwith the case group by sex, age,
and ethnicity.
2.2. Audiological Equipment. Pure tone threshold audiome-
try was performed within a sound-proof cabin (model E2X2,
roll 01008 220V 10A;Mercury,Milan, Italy) using anAmplaid
audiometer (Amplaid, Milan, Italy), calibrated to ISO 9001
standards. The audiometric procedure was performed using
headphones to assess air conduction and a bone vibrator
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for bone conduction. The better ear was evaluated first. An
ascending method using 5 dB HL steps was utilized to cal-
culate hearing threshold. Air conduction hearing thresholds
were assessed at 125, 250, 500, 1000, 2000, 4000, and 8000Hz.
Bone conduction hearing thresholds were assessed with the
use of a masking, white, and contralateral noise, at 250, 500,
1000, 2000, and 4000Hz.
2.3. Genetic Investigations. All enrolled patients (𝑛 = 200)
underwent DNA analysis for the identification of specific
genetic variants in 4 iron-related genes: FPN1 (SLC40A1)
(ferroportin),TF (transferrin),HFE (humanhemochromato-
sis gene), and HEPC/HAMP (hepcidin). All these genes are
known to play a crucial role in iron homeostasis with increas-
ing evidence of involvement in inner ear pathophysiology.
The following polymorphisms were examined:
(i) FPN1, 5󸀠UTR c.−8CG,
(ii) TF, C1 and C2 variants (p.P570S),
(iii) HFE p.H63D and p.C282Y,
(iv) HEPC, 5󸀠UTR c.−582AG.
DNA was isolated from peripheral frozen whole blood
by an automated DNA extraction and purification robot
(BioRobot EZ1 system from QIAGEN; Hilden, Germany),
which performs purification of nucleic acids using amagnetic
bead technology.
PCR amplifications were performed by means of the
lyophilic complete UNIVERSAL MASTER MIX kit (STAT-
NAT DNA-Mix; SENTINEL Diagnostics, Milan, Italy) con-
taining all the reagents useful to amplify the extracted DNA
with the exclusion of the specific pair of primers. The PCR
cycle for the different SNP containing fragments was as
follows: HFE, FPN1, HEPC, and TF (one cycle of denaturing
at 95∘C/5min followed by 33 cycles of 94∘/30 sec; 57∘/30 sec;
72∘/60 sec). PCRs were performed in a PTC-200 thermal
cycler (M. J. Research, Inc., Watertown, MA, USA). SNP
detection was performed using the Pyromark ID System
(Biotage AB Uppsala, Sweden) according to the standard
procedures for amplicon denaturation, purification, and
sequencing following the manufacturer’s recommendations.
All the oligo sequences of the SNPs investigated (Forward,
Reverse, and Sequence primers) were selected to have an at
least 98.0% compatibility score.
Haplotypes were confirmed by regenotyping of approx-
imately 20% of randomly selected samples among each
different genotype group for each specific polymorphism
by means of enzymatic restriction of PCR amplicons. All
the digestion reactions were performed according to the
supplier’s instructions. There were no discrepancies between
genotypes determined in duplicate and/or by different meth-
ods. Known genotypes were used as control references.
Additional nonreported technical details are as previously
described [10].
Written informed consent was obtained from all par-
ticipants according to current national rules and laws for
publication. All further research was conducted in accor-
dance with the ethical standards of all applicable national
Table 1: Main characteristics of the population investigated.
Cases Controls 𝑃 value
Number 200 400 —
Age mean ± SD
median, range 63.65, (10–92) 63.5, (10–92) NS
Male/female 96/104 190/210 NS
Left side 95 — —
Right side 103 — —
Bilateral 2 — —
Mild hearing loss 44 — —
Moderate 92 — —
Severe 33 — —
Profound 31 — —
and institutional committees and with the World Medical
Association’s Helsinki Declaration.
2.4. Statistical Analysis. Significant differences among groups
were assessed by chi-square test for genotype distribution
comparisons. When appropriate, Yates’ correction or Fisher’s
exact test was applied. Adjusted odds ratios (OR) and
95% confidence intervals (95% CI), calculated by logistic
regression models were used to estimate the risk associated
with the presence of the rare homozygous condition (e.g.,
FPN1 −8GG, Tf C2C2, HFE 63DD, and HEPC-582GG) or
with the heterozygotes (i.e., HFE 282CY) compared with the
remaining genotypes (i.e., heterozygous and/or homozygous
for the common allele) in cases versus the controls according
to a recessive model of phenotype expression.
3. Results
3.1. Single Analyses. A total of 200 patients affected by
ISSNHL and referred to the ENT and Audiology Department
of the University Hospital of Ferrara between January 2009
and December 2013 were included in this study. Of these,
104 (52%) were females and 96 (48%) were males; quietly all
(𝑛 = 198; 99%)were unilateral cases (103; 51.5% right side and
95; 47.5% left side), and 2 (1%) cases were bilateral; themedian
age was 63.65 years (age range: 10–92 years) (Table 1).
The DNA of the 200 patients was sampled and analyzed
to identify the polymorphism −8CG of the FPN1 gene
promoter region. A total of 123 (61.5%) patients were −8CC
homozygotes, 62 (31%)were heterozygotes, and 15 (7.5%)were
−8GG homozygotes.
The same 200 patientswere searched for the variantH63D
of the HFE gene: 56 (28%) were heterozygous; 2 (1%) cases
were 63DD homozygotes, and the remaining 142 (71%) were
63HH homozygotes.
Concerning the polymorphism analysis for the C282Y
HFE gene, we identified 7 (3.5%) cases as 282CY heterozy-
gotes and no 282YY homozygous were found. Furthermore,
12 (6%) cases presented the polymorphism −582AG in the
HEPC gene in homozygosis (GG) and 77 (38.5%) in heterozy-
gosis (AG), whereas the remaining 111 (55.5%) cases did not
present the genetic variant.
4 BioMed Research International
Table 2: Gene variants distribution and associated ORs values. The ORs have been calculated comparing the number of the polymorphic
homozygotes with the rest of genotypes among cases versus the controls.
Gene variant FPN1 (SLC40A1) Tf HFE HFE HEPC (HAMP)
−8CG C1, C2 H63D C282Y −582AG
Cases 200 200 200 200 200
Controls 400 400 400 400 400
Genotypes CC CG GG C1C1 C1C2 C2C2 HH HD DD CC CY AA AG GG
Cases 123 62 15 139 53 8 142 56 2 193 7 111 77 12
% 61.5 31 7.5 69.5 26.5 4 71 28 1 96.5 3.5 55.5 38.5 6
Controls 268 125 7 270 119 11 294 98 8 383 17 229 147 24
% 67 31.25 1.75 67.5 29.75 2.75 73.5 24.5 2 95.75 4.25 57.25 36.75 6
𝑃 value 0.001 0.63 0.55 0.80 0.92
OR (95% CI) 4.27 (2.65–6.89) 1.39 (0.71–2.73) 0.52 (0.13–2.08) 0.82 (0.33–2.0) 1.03 (0.60–1.76)
Alleles C G C1 C2 H D C Y A G
Cases number/% 308/77 92/23 331/82.75 69/17.25 340/85 60/15 393/98.25 7/1.75 299/74.75 101/25.25
Controls
number/% 661/82.6 139/17.4 659/82.4 141/17.6 686/85.7 114/14.3 783/97.9 17/2.1 605/75.6 195/24.4
𝑃 value 0.02 0.94 0.79 0.83 0.79
OR (95% CI) 1.42 (1.06–1.91) 0.97 (0.71–1.34) 1.06 (0.76–1.49) 0.82 (0.34–1.99) 1.05 (0.8–1.38)
Table 3: Hearing loss severity score stratified by different genotypes among the different gene variants: 44 (mild), 92 (moderate), 33 (severe),
and 31 (profound). HL severity score is graded in the following: mild hearing loss (16–40 dBHL), moderate hearing loss (41–70 dBHL), severe
hearing loss (71–90 dBHL), and profound hearing loss (>90).
Gene variant FPN1 (SLC40A1) Tf HFE HFE HEPC (HAMP)
−8CG C1, C2 H63D C282Y −582AG
Cases 200 200 200 200 200
Genotypes CC CG GG C1C1 C1C2 C2C2 HH HD DD CC CY AA AG GG
Total (𝑛) 123 62 15 139 53 8 142 56 2 193 7 111 77 12
HL severity score (PTA dB HL)
16–40 dBHL 27 12 5 27 16 1 31 13 0 42 2 34 6 4
41–70 dBHL 60 26 6 66 24 2 62 28 2 88 4 51 35 6
71–90 dBHL 18 12 3 21 8 4 25 8 0 32 1 12 19 2
>90 dBHL 18 12 1 25 5 1 24 7 0 31 0 14 17 0
Finally, the presence of the two variants C1 and C2 of the
transferrin protein yielded 8 (4%) patients C2C2 homozy-
gotes, 53 (26.5%) C1C2 heterozygotes, and 139 (69.5%) C1C1
homozygotes for the isoforms (Table 2).
The homozygous genotype c.−8GG of the SLC40A1 gene
revealed an OR for ISSNHL risk of 4.27 (CI 95%, 2.65–
6.89; 𝑃 = 0.001), being significantly overrepresented among
cases. No significantORswere observed under the additive or
dominant/recessivemodels for the analysis in the other genes
investigated.
3.2. Combined Analyses. In attempt to calculate a cumulative
HL risk associated with the coexistence of multiple predis-
posing genotypes, we compared the whole group of cases
and controls carrying a combination of different polymorphic
alleles. In detail, subjects carrying at least four “risk-alleles”
in at least two different SNPs (multicarriers) were computed
and compared with subjects who were homozygous for the
common allele in all the considered gene variants (fully
wild-types). Combined homozygotes at least in two different
SNPs, single homozygotes in one, and combined carriers in
at least two, or carrying at least a quadruple heterozygous
condition, they globally were 7.0% in patients (𝑛 = 14)
and 4.75% in controls (𝑛 = 19). Conversely, the fully wild-
type condition was 18.5% in cases (𝑛 = 37) and 19.0% in
controls (𝑛 = 76). Although the slight trend observed in
the overrepresentation of the rare at risk combined alleles, no
significant risk-values were obtained from this kind of com-
parison (OR = 1.51; CI 95%, 0.68–3.35) Finally, stratifying the
groups of patients by their hearing loss score, no significant
correlation was observed between a particular allele and the
clinical severity (Table 3).
4. Discussion
Sudden hearing loss has been reported to be associated with
a huge number of clinical conditions [35–38]. The uncer-
tainty of reasonable etiologies has encouraged continuous
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Mus musculus
Rattus norvegicus
Sus scrofa
Bos taurus
Capra hircus
Homo sapiens
Start (Met)
AGGGGAGAGCGTCTGGTGCCATGACCAAGTCAAGAGATCAGACCCATCAG 321
AGTGGGGGTCGCCTTGTGTCATGACCAGGGCAAGAGAGCAAAACCGCCAG 349
AGCGGGGGGCGTCTGGTGTCATGACCAGGACAAGAGAGCAGAGCCGTCAG 191
AGCGGGGGGCGTCTGGTGTCATGACCAGGACAAGAGAGCAGAGCCGTCAG 246
AGCGGGG-TCGCCTAGTGTCATGACCAGGGCGGGAGATCACAACCGCCAG 334
FPN1 (SLC40A1)
AGGGGAGAACGCCTGGTGTCATGACCAAGGCAAGAGATCAAACCCATCAG 327
−8CG
Figure 1: The panel shows how much the promoter region of SLC40A1 gene containing the polymorphic nucleotide is conserved among
different kinds of mammals. ClustalW2 http://www.ebi.ac.uk/.
investigations aimed at identifying the most convincing
pathological explanation. Moreover, it has encouraged new
considerations of the predisposing genetic conditions that
might explain the clinical variability when a positive correla-
tion with factorial events occurs. Far from the identification
of an unequivocal mutated gene, the study of genetic variants
appears to better meet researcher expectations even when
such variants actually cannot be paired with the unilateral
manifestation of ISSHL. In addition, previous studies have
reported the correlation of various polymorphisms with an
increased [39–43] or reduced [44] risk of developing hearing
impairment. Thus, currently, the definition of new pathways
of molecular interactions is essential in supporting genetic
observations (Figures 1–3).
Recent advanced findings in regards to ROS-mediated
damage and nitric oxide (NO) activity have encouraged
researchers to focus their studies on possible connections
between microvascular damage and free radical produc-
tion. The study of polymorphisms of genes related to iron
metabolism in relation to SSNHL has not been previously
reported: we hypothesized that these variants could also be
involved in the pathogenesis of SSNHL [45]. Nonetheless,
the role of ferroportin in managing the delicate iron redox
balance at the level of the cochlea or the auditory nerve
is still unclear [46]. However, it is possible to assume that,
under stressful conditions, cells need to rapidly reduce the
intracellular free divalent iron pool, and this can produce
oxidative damage. Moreover, increased levels of Fe2+ inhibit
the intracellular production of NO, a fundamental element
in the regulation of local microcirculation. Nitric oxide has a
decisive role in the regulation of cochlear flow.We can divide
the inner ear into four large anatomofunctional districts:
(1) homeostasis of labyrinthine fluid, (2) stria vascularis, (3)
organ of Corti, and (4) neurons and spiral ganglion. Mito-
chondria could be considered as the center of connection
of these parts or as a fifth district [47–49]. Thus, unilateral
sudden hearing loss might be considered the consequence of
recurrent aggression of important inner ear structures that,
in the end, leads to local damage with trigger points that
are linked to general clinical conditions, comorbidity, and
functioning local anatomy.These elements might explain the
age of onset and unilateral expression of the disease.
The auditory system might be optimized to minimize
the persistence and the concentration of divalent metal
ions in the inner ear fluids [50]. This homeostatic system
is finely tuned to prevent, ultimately, damage to the sen-
sorineural cells, without compromising the function of vital
Start of Start of 
IRE
Promoter region
IRP
−98GC −8CG
−235 −196
5󳰀 3
󳰀
transcription translation
Figure 2: Schematic representation of the hairpin of the iron reg-
ulatory element (IRE) interacting with the iron regulatory protein
(IRP) in the FPN1 promoter region. It is to note the closeness of the
−98GC SNP to the “beginning” of the IRE sequence.
processes dependent on the presence of iron, especially at
the mitochondrial level (Figure 3). Studying the location of
other proteins involved in the metabolism of iron (ferritin,
transferrin, andDMT1), we determined a precise localization
of the ferroportin in the associated pathway and speculated
on possible effects of the polymorphism FPN1 −8CG in
the promoter area (Figure 2). This polymorphism belongs
to a group of iron gene variants previously investigated
by our group in other complex diseases in which iron-
driven inflammation or anomalous redox balance may have
a role or be suspected (10, 13, 14, 19). On the basis of the
assumption that they are not the only ones responsible for the
disease, they could instead act together with something not
completely known (often acquired but not exclusively) and
account for the establishment of the pathological condition.
In detail, the five variants are relatively common in the
racial group investigated and are selected just to sound our
theory not considering this fact as definitive and completely
exhaustive. Finally, having performed in this study a case-
control comparison in which the two groups completely
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Blood vessel
Transferrin/Fe3+
Transferrin/Fe3+
Transferrin/Fe3+
Transferrin/Fe3+ Transferrin/Fe3+
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Ferritin
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junctions
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Stria vascularis
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cytoplasmatic
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↓↓↓ Fe2+
↓↓ Fe2+
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DMT1
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? FPN1/gap ? FPN1/
? FPN1/gap
? FPN1 150mM K
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Figure 3: Divalentmetal ion homeostasis in the inner ear.The picture shows a schematic representation of a section of the inner ear; reviewing
the literature allowed the speculation around the potential involvement of specific proteins in the iron homeostasis. Considering distribution
and function of those proteins it may be possible that iron ions follow a cycle similar to the potassium cycle, also through gap junctions. In
particular, transferrin is concentrated in perilymph and cerebrospinal fluid and it transports trivalent (ferric) ions from and to blood vessels.
In addition iron ions are stocked in the stria vascularis (ferritin depots). In fact, the apical expression of DMT1 is reasonably involved in
reabsorption of free divalent ions from inner ear fluids thus maintaining electrochemical features. Cytoplasmic DMT1 allows the uptake of
molecules of transferrin through Tf receptors. Ferroportin (FPN 1) is basolaterally located and probably helps inner ear cells in the reuptake
of divalent ions, taking them away from the sensorineural epithelium during acoustic stimulation to avoid free radical damage. Ions are
taken off through the basolateral part of cells and “pushed” towards spiral ganglion and stria vascularis. It is possible that divalent ions pass
through gap junctions (metal divalent ion diameter could be less than 1 nanometer; thus molecules can passively diffuse through connexons
in the intercellular space). Summarizing, divalent ions are transported from area with few blood vessels and low ferritin concentrations, to
the structures that can storage or evacuate divalent ions, such as stria vascularis. Outer and inner ear cells may introduce a small amount of
divalent ions through calcium channels.
matched for sex, age, and ethnicity, we can exclude that the
overrepresentation of the allele FPN1-8G, observed among
cases, could be due to a particular ethnicity who selects a
particular gene variant or to other influencing factors.
Accordingly, NO, free radicals (ROS), and NF𝜅B might
potentially be involved during inner ear fluid homeostasis.
The interaction of these elements ultimately involves other
proteins with the precise purpose of regulating the local
inflammatory response, blood flow, and cellular activity
(including mitochondrial activity) [51–54]. For example, the
stria vascularis, in its basal layer and the intermediate layer,
reactsmainly toward a response to inflammationmediated by
NF𝜅B [55–57]. In another district or below a certain degree of
local aggression, an antioxidant responsemediated byNFRE-
2 is favored, especially at the level of the organ of Corti.
The expression of ferritin [58] and the concomitant apical
expression of DMT1 [59] suggest that the stria vascularis
has an active role in restoration and deposition of iron,
with particular attention to reducing the endolymphatic
concentration of divalent ions [60, 61]. Accordingly, it is
known that free radical stress-mediated loss of specific
protein expression (i.e.,Kcnj10) in stria vascularis contributes
to hearing loss in Pendred syndrome mouse model [18].
Pendred syndrome, the most frequent hereditary form of
syndromic deafness, is caused by loss-of-function mutations
of the gene SLC26A4, which encodes the anion exchanger
pendrin [62]. Transient/constitutive reduction of Kcnj10
protein expression under free radical stress could be the
pathobiologic mechanism of sudden hearing loss that could
be not limited just to Pendred syndrome. SLC26A4 and
SLC40A1 genes belong to the same (super)family and might
be involved, by regulating inflow/outflow of different ions, to
maintain specific homeostasis and redox potency [63]. Stria
vascularis is sensitive to free radical stress due to its high
metabolic activity and dense vascular system [64] and when
iron-chelator proteins are not adequately functioning or are
BioMed Research International 7
not enough to contrast and neutralize the detrimental effect
of iron this situation could dramatically affect the optimal
stria vascularis functions.
We could also hypothesize/speculate amechanismof sup-
plementation of divalent ions into the endolymphatic space
affecting the volume and the acidification of the endolymph,
both affected in the Pendred syndrome. Nevertheless, this
role is most likely less important than the reuptake because
of the endolymphatic electrical gradient.
Iron is predominantly bound to transferrin that is present
in increasing respective concentrations in perilymph, cere-
brospinal fluid, and blood [65–67]. This could explain the
intracytoplasmic expression and localization of DMT1 in the
organ of Corti. Conversely, DMT1 is absent at the level of
the ciliated cells and highly expressed at the level of neuronal
fibers and in particular of the basal ganglion. Summarizing,
changes in the redox capacity of a system affect indeed
the pH with drastic biological effects. These data suggest a
similar involvement of ferroportin as indicated above and
are in agreement with kidney analogous distribution [68].
Furthermore, the receptors for transferrin might mediate the
internalization of vesicles in ciliated cells by TfR [69]. These
receptors must be absent in the ciliated cells, and the iron
may enter in a minimum amount, finely controlled, most
likely through the basolaterally expressed calciumchannels in
ciliated cells: L-type calcium channels, localized basolaterally
in hair cells that could allow the intake of a few molecules
of Fe2+ [70–76]. An intercellular passage at the level of the
inner ear through the gap junctions cannot be excluded. In
fact, the diameter of the channels formed by the connection
would allow the passage of molecules such as divalent metal
ions, as these, especially in the case of the iron, are less than
2 nm in diameter and very close in size to calcium ions that
habitually take advantage of the gap junction for cytoplasmic
passage from cell to cell [77]. The gradient that the free iron
could exploit is that of bidirectional facilitated diffusion: iron
might be able to “spreading out” in case of accumulation and
“coming back” in case of consumption if necessary. According
to this circle, this type of iron distribution calls to mind
in some aspects the recirculation of the potassium ions but
most likely with opposite direction.The longitudinal gradient
that is already physiologically present along the cochlea (the
concentration of endolymphatic potassium increases from
the apex to the base) might play a role in the flow of divalent
ions [78], especially in pathological conditions.
Summarizing, FPN1−8CGgene polymorphismdisplayed
a significant association with ISSNHL, as patients carrying
this polymorphism displayed an increased risk of develop-
ing this disease in adulthood. The distribution of proteins
involved in the recirculation of divalent metal ions leads us
also to believe that ferroportin is coupled to the expression of
DMT1. The distribution of DMT1 is superficial at the level of
the stria vascularis where we find the largest concentration of
ferritin [58, 79]. The task of reabsorption of divalent metals,
including iron, with the possibility of storage, is most likely
performed by the stria vascularis [80]. On the contrary,
the nerve fibers, spiral ganglia of the organ of Corti (with
the exception of ciliated cells internal and external), display
cytoplasmic localization ofDMT1 [81].This suggests a system
of mobilization of iron, or of other divalent metals, mediated
by transferrin, which, in fact, is more represented in the
perilymph and in the cerebrospinal fluid, which is in contact
with the organ of Corti and nerve bundles.
Conversely, the outer and inner hair cells do not appear
to express DMT1. This does not necessarily exclude the
expression of FPN1 at this level. Nevertheless, it suggests how
neurosensory cells might be excluded as much as possible
from redox activities, inflammatory responses, and ionic
movements, most likely because of their specific nature.
Ferroportin is the main mammalian iron exporter, and
by means of the homozygous gene variant condition (−8GG)
could affect the local iron levels poisoning microenviron-
ment. In this context, it is reasonable to assume that the
polymorphism, by affecting the expression of ferroportin,
could modify the iron homeostasis at the local level. Though
the nucleotide substitution is not strictly close to the IRE (iron
regulatory element) region of the gene, it is in strong dise-
quilibrium with the −98GC variant (Figure 2) that is instead
more close [82]. Then, by virtue of the documented high
conservation of this promoter gene area among mammals
(Figure 1), it could be possible that one or both of these
variants dysregulated optimal FPN1 function by affecting the
IRE-IRP signaling pathway. In addition, it is to take into
account that macrophages carry on their surface the FPN1
receptor and that they contribute to the degeneration of the
stria vascularis in Pendred syndrome [83]. Accordingly, an
altered macrophage action could further worsen the critical
homeostasis in terms of iron overload and related oxidative-
stress as previously suggested in different degenerative dis-
eases considering that the “mutated” macrophages might
increase the possibility of generating free iron and free
radicals, possibly leading to matrix breakdown and cell death
[14, 84] (Figure 3).
In conclusion, further larger epidemiological studies are
required to elucidate the pathophysiological mechanisms.
Such a complex disease is to consider a multifactorial and
polygenic condition in which gene-environment interactions
have a key role. In particular, on the basis of the iron-
driven hypothesis and that of the oxidative stress, additional
correlated gene variants could be considered as well as
those involved in the homocysteine, metalloprotease, or
hemopexin pathways possibly playing a role in this complex
biochemical mechanism.
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